"Matter of Time" Documentary on EB Research Kicks Off Global Screenings in Over 30 Cities

"Matter of Time," a documentary chronicling the global effort to raise awareness and find a cure for Epidermolysis Bullosa (EB), is set to launch its special global screening event next month. The film, which features Pearl Jam frontman Eddie Vedder, will begin its theatrical run in over 30 cities, commencing November 7th with a week-long engagement at West Seattle’s Admiral Theater. The announcement, shared by Pearl Jam on social media, highlights the growing campaign against the rare genetic disease.

Epidermolysis Bullosa is a devastating genetic disorder characterized by extremely fragile, blistering skin, often leading to severe pain and complications, with affected children sometimes referred to as "Butterfly Children." Eddie Vedder and his wife, Jill Vedder, co-founded the EB Research Partnership (EBRP) in 2010, driven by a personal connection to the disease. The documentary is largely set against the backdrop of Vedder's two sold-out solo concerts at Seattle’s Benaroya Hall in October 2023, which successfully raised over $5 million for critical EB research.

Directed by Matt Finlin and produced by Door Knocker Media in association with EBRP and the Vitalogy Foundation, "Matter of Time" interweaves Vedder’s powerful performances with intimate stories from patients, families, and leading researchers. Michael Hund, CEO of EB Research Partnership, stated, "This film celebrates our community of courageous patients and families, and highlights the real scientific progress that is happening right now." Jill Vedder further emphasized the urgency, noting, "This is more than awareness; it's an urgent push to cure EB by 2030."

EBRP employs an innovative venture philanthropy model, which has significantly advanced EB research by raising over $70 million and contributing to a 20x growth in clinical trials, including funding the first FDA-approved topical gene therapy for the condition. This model aims to accelerate cures for EB and establish a scalable blueprint for treating thousands of other rare diseases, impacting over 400 million people globally. The documentary serves as a powerful rallying cry, demonstrating how collective determination and scientific innovation are redefining possibilities in medicine.

Following its world premiere at the Tribeca Film Festival and its recognition as Best Music Documentary at the Nashville Film Festival, the film's expanded global theatrical release aims to broaden its reach and impact. Pearl Jam confirmed that "additional theatrical dates are planned, with more information to follow," urging fans and advocates to learn more at the film's official website. The initial week-long run in West Seattle is anticipated to draw considerable attention to the ongoing fight for a cure.